In Vitro Diagnostics Market Research Reports & Industry Analysis

The publications below represent comprehensive market research on components of the global market for in vitro diagnostics. Reports, published by several different research companies, address financial analyses of major companies, overview analyses of the global market, and specific analyses on individual countries or individual and more specific segments of the market, such as cell analysis.
...Show More ...Show Less


In Vitro Diagnostics Industry Research & Market Reports

  • Life Science Instrumentation

    ... at a CAGR of 4.6% over the analysis period 2024-2030. Spectroscopy Technology, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$24.4 Billion by the end of ... Read More

  • Plasma Fractionation

    ... CAGR of 5.1% over the analysis period 2024-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$14.8 Billion by the end of the analysis period. ... Read More

  • Predictive and Presymptomatic Testing

    ... 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 12.7% CAGR The Predictive and Presymptomatic Testing market ... Read More

  • Sepsis Diagnostics

    ... CAGR of 7.5% over the analysis period 2024-2030. Microbiology Technology, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$749.8 Million by the end of the analysis ... Read More

  • Plasma Therapy

    ... CAGR of 7.4% over the analysis period 2024-2030. Pure PRP, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$468.4 Million by the end of the analysis ... Read More

  • Pregnancy Detection Kits

    ... at a CAGR of 4.8% over the analysis period 2024-2030. Home Pregnancy Tests (HPT), one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$805.2 Million by the ... Read More

  • Mice Model

    ... CAGR of 5.3% over the analysis period 2024-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of ... Read More

  • Mycotoxin Testing

    ... CAGR of 5.9% over the analysis period 2024-2030. Spectroscopy- & Chromatography-Based Technology, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$1.6 Billion by the end of ... Read More

  • Influenza Diagnostics

    ... CAGR of 5.2% over the analysis period 2024-2030. RIDT Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More

  • Protein Binding Assays

    ... at a CAGR of 9.4% over the analysis period 2024-2030. Equilibrium Dialysis Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$342.2 Million by the end ... Read More

  • Pneumonia Testing

    ... CAGR of 6.2% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$339.9 Million by the end of the analysis period. ... Read More

  • Breath Analyzers

    ... CAGR of 15.4% over the analysis period 2024-2030. Fuel Cells Technology, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$2.6 Billion by the end of the ... Read More

  • Antithrombin

    ... 5.3% over the analysis period 2024-2030. Therapeutics Application, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$847.5 Million by the end of the analysis period. Growth ... Read More

  • Cervical Dysplasia Diagnostics

    ... at a CAGR of 5.9% over the analysis period 2024-2030. Diagnostic Tests, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$793.8 Million by the end of ... Read More

  • Drugs of Abuse Testing

    ... 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Analyzers, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$2.9 Billion by the end ... Read More

  • Point of Care (POC) Molecular Diagnostics

    ... reach US$8.8 Billion by 2030, growing at a CAGR of 12.9% over the analysis period 2024-2030. Infectious Diseases Application, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and ... Read More

  • In Vitro Toxicology Testing

    ... 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Cell Culture Technology, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$11.2 Billion by ... Read More

  • Immunofluorescence Assays

    ... CAGR of 4.4% over the analysis period 2024-2030. Immunofluorescence Assay Reagents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.8 Billion by the end of the ... Read More

  • Cell Lysis / Cell Fractionation

    ... Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Cell Lysis / Cell Fractionation Consumables, one of the segments analyzed in the report, is expected to record a 6.7% CAGR ... Read More

  • Cell Signaling

    ... CAGR of 5.4% over the analysis period 2024-2030. Cell Signaling Consumables, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$4.5 Billion by the end of the ... Read More

  • Drug Abuse Testing

    ... at a CAGR of 5.3% over the analysis period 2024-2030. Laboratory Services, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$52.0 Billion by the end of ... Read More

  • Fertility Services

    ... CAGR of 15.0% over the analysis period 2024-2030. Fresh Non-Donor Fertility Services, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$75.3 Billion by the end of ... Read More

  • Flow Chemistry

    ... CAGR of 8.8% over the analysis period 2024-2030. CSTR, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.1 Billion by the end of the analysis period. ... Read More

  • Cell Proliferation Kits

    ... at a CAGR of 5.5% over the analysis period 2024-2030. Pharma & Biotech Companies End-Use, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$394.2 Million by ... Read More

  • C-Reactive Protein Testing

    ... at a CAGR of 1.7% over the analysis period 2024-2030. Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$1.0 Billion by the end of ... Read More

Cookie Settings